Oncology Medical Centers

University of Alabama: Clinical research is being conducted on the use of a ribonuclease protein + doxorubicin vs. doxorubicin, in patients with unrespectable malignant Mesothelioma cancer.; Contact: Karen Harper, RN, BSN; University of Alabama at Birmingham Comprehensive Cancer Center; 1824 Sixth Avenue South; Birmingham, AL 35294-3300; Telephone: 205-934-5092; Email: Karen.Harper@ccc.uab.edu

California

Tower Hematology/Oncology: Study of an investigational treatment for malignant mesothelioma patients; Contact: Dee Volkerts, Study Coordinator; Tower Hematology/Oncology; 8635 West Third Street, Suite 665W; Los Angeles, CA 90048
Sharp Health Care: Study of an investigational treatment for malignant mesothelioma patients.; Contact: Cathy K. Wood, Manager, Oncology Research Program; Sharp Health Care; 10835 Road to the Cure; San Diego, CA 92121; Telephone: 858-450-5990 ext. 221

University of Colorado: Study of an investigational treatment for malignant mesothelioma patients.; Contact: Monica Robischon, Study Coordinator; University of Colorado; 4200 East 9th Avenue, B-189; Denver, CO 80262; Telephone: 303-372-9108

Oncology Hematology Group of South Florida: Study of an investigational treatment for malignant mesothelioma patients.; Contact: Cathy Maxwell, Study Coordinator; Oncology Hematology Group of South Florida; 8940 North Kendall Drive, Suite 300E; Miami, FL 33176; Telephone: 305-594-2141 ext. 286

University of Chicago Medical Center: Study of an investigational treatment for malignant mesothelioma patients.; Contact: Tamara Guterz, Study Coordinator; University of Chicago Medical Center, Section of Hematology/Oncology; 5841 S. Maryland Avenue, MC2115; Chicago, IL 60637-1470; Telephone: 773-834-3137

Kentuckiana Cancer Institute: Study of an investigational treatment for malignant mesothelioma patients.; Contact: Roxanne Smalley; Kentuckiana Cancer Institute; 100 E. Liberty Street, Suite 502; Louisville, KY 40202; Telephone: 502-561-8200

Umass Memorial Cancer Center: Study of an investigational treatment for malignant mesothelioma patients; Umass Memorial Cancer Center; Division of Hematology/Oncology; 55 Lake Avenue North; Worcester, MA 01655-001; Telephone: 508-856-1385; Email: judith.odonnell@banyan.ummed.edu

Somerset Medical Center: Study of an investigational treatment for malignant mesothelioma patients.; Contact: Oncology Clinical Research Coordinator; Somerset Medical Center; 110 Rehill Avenue; Somerville, NJ 08876; Telephone: 908-685-2481; Email: jcraig@somerset-healthcare.com

Columbia-Presbyterian Medical Center: Phase II trial of combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for treatment of peritoneal mesothelioma.; Contact: Mary Hesdorffer, RN, BSN, Clinical Research Nurse; Columbia-Presbyterian Medical Center; 161 Fort Washington Avenue; New York, NY 10032; Telephone: 212-305-1252

Presbyterian Medical Center, University of PA Health System: Study of an investigational treatment for malignant mesothelioma patients.; Contact: Pat Drobins, Study Coordinator; Presbyterian Medical Center, U. PA Health System; Medical Arts Building; 51 North 39th Street; Philadelphia, PA 19104; Telephone: 215-349-8913

Thompson Cancer Survival Center: Study of an investigational treatment for malignant mesothelioma patients; Contact: Sue Thompson, RN, Manager, Clinical Trials; Thompson Cancer Survival Center; 1915 White Avenue; Knoxville, TN 37916; Telephone: 865-541-1893; Email: sbales@corhlth.com

Lone Star Oncology: Study of an investigational treatment for malignant mesothelioma patients.; Contact: Tracy Bell, Study Coordinator; Lone Star Oncology; 11044 Research Boulevard, Suite D400; Austin, TX 78759; Telephone: 512-343-2103; Email: drjjjc@aol.com
S. R. Burzynski Clinic: Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Mesothelioma; Contact: Oncology Department; S. R. Burzynski Clinic; 9432 Old Katy, Suite 200; Houston, TX 77055; Telephone: 713-335-5697
MD Anderson Cancer Center: Study of an investigational treatment for malignant mesothelioma patients.; Contact: Oncology Department; MD Anderson Cancer Center; Department of Thoracic Head & Neck Med Onc, Box 432; 1515 Holcombe Boulevard; Houston, TX 77030; Telephone: 713-792-7033 ext. 3141

H.O.P.E.: Study of an investigational treatment for malignant mesothelioma patients.; Contact: Hematology Oncology Department; 459 Locust Ave.; Charlottesville, VA 22902; Telephone: 434-982-8410
Virginia Oncology Associates: Study of an investigational treatment for malignant mesothelioma patients.; Contact: Virginia Oncology Associates; 895 Middle Ground Boulevard #200; Newport News, VA 23606; Telephone: 757-873-9400